Lenalidomide Krka d.d. Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Tavneos Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - Ανοσοκατασταλτικά - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Enjaymo Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - Ανοσοκατασταλτικά - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).